In HFrEF, potassium binders are best reserved for confirmed, persistent, or recurrent hyperkalaemia that would otherwise force interruption or down-titration of indicated RAAS inhibition, especially an MRA. Their established benefit is potassium control and helping some patients stay on therapy, not proven reductions in mortality or heart-failure hospitalization.

Why It Matters To Your Practice

• RAAS inhibitors, particularly MRAs, are beneficial in HFrEF, but hyperkalaemia can limit their use.

• A 2022 AHA/ACC/HFSA HFrEF guideline cited here recommends starting an MRA only if eGFR is above 30 mL/min/1.73 m² and serum potassium is below 5.0 mmol/L, with close monitoring afterward. An MRA should be discontinued if potassium cannot be maintained below 5.5 mmol/L. So binders are not a workaround for uncontrolled hyperkalaemia or unmet starting criteria alone.

Clinical Implications

• Before using a binder, confirm the potassium result and look for reversible contributors such as potassium supplements or salt substitutes, NSAIDs, trimethoprim, acute kidney injury, constipation, metabolic acidosis, or inadequate diuresis in a congested patient.

• Around potassium 5.0 to 5.5 mmol/L during treatment, trend, kidney function, and recurrence matter more than an automatic stop. A binder can be reasonable if repeated elevations are jeopardizing continued RAASi use despite corrective steps and planned monitoring of potassium and kidney function. At or above 6.0 mmol/L, with a rapidly rising value, symptoms, or ECG changes, urgent assessment is needed; oral binders do not replace emergency treatment, per a UK Kidney Association hyperkalaemia guideline cited here.

Insights

• The two main agents differ in ways that matter in HFrEF. Patiromer does not carry the sodium load associated with sodium zirconium cyclosilicate, but it can cause gastrointestinal intolerance, hypokalaemia, and hypomagnesaemia, and other oral medicines generally need to be separated by 3 hours.

• Low magnesium may increase arrhythmia susceptibility, especially when paired with hypokalaemia, QT-prolonging drugs, digoxin, diuretics, or prior ventricular arrhythmia. However, the material cited here does not establish excess ventricular arrhythmias from patiromer-induced magnesium lowering in HFrEF trials. Magnesium should be checked alongside potassium and kidney function during treatment, especially after changes or if symptoms occur. Magnesium correction may be needed to resolve accompanying hypokalaemia, not the original hyperkalaemia indication for the binder itself. New syncope, sustained palpitations, or suspected arrhythmia warrants prompt assessment and ECG evaluation. An isolated mildly low magnesium value should be interpreted in clinical context, not as a stand-alone marker of arrhythmic danger. Low magnesium can also increase renal potassium loss, making hypokalaemia harder to correct when it develops on treatment. Separately, sodium zirconium cyclosilicate acts faster but contains about 400 mg sodium per 5 g dose; oedema is recognized, and REALIZE-K reported more worsening-heart-failure events with sodium zirconium cyclosilicate than placebo despite better potassium control and spironolactone maintenance. That finding was exploratory in a trial not powered for clinical outcomes, so it supports caution rather than proving causation.

The Bottom Line

• Use a potassium binder in HFrEF when recurrent hyperkalaemia is truly threatening beneficial RAAS inhibition after reversible causes are addressed and a monitoring plan is in place.

• Choose the agent with its tradeoffs in mind: patiromer raises concern about hypomagnesaemia and drug spacing, while sodium zirconium cyclosilicate raises concern about sodium load, oedema, and possible heart-failure worsening. Neither justifies continuing RAAS inhibition through uncontrolled hyperkalaemia, and neither has established outcome benefit beyond potassium control.

Please review content for accuracy. You are the final authority.